Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507997 | 0.83 | FDPS (0.35) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL5004595 | 0.83 | FDPS (0.35) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL28340215 | 0.79 | FDPS (0.44) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL27734755 | 0.73 | FDPS (0.40) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL28271008 | 0.72 | FDPS (0.35) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL28444794 | 0.72 | FDPS (0.35) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL27783128 | 0.71 | FDPS (0.39) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL6055010 | 0.71 | FDPS (0.39) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL27714206 | 0.70 | FDPS (0.38) | FDPSLTA4HMKNK2HDAC1HDAC6 | |
| SCHEMBL11345735 | 0.69 | TLR7 (0.51) | FDPSLTA4HHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108070566-A | The stem cell screening model of sitaxsentan sodium object and application | 中国医学科学院基础医学研究所 | 2018-05-25 | — | — | CN | disclosed |
| CN-105062976-B | Stem cell screening model of pulmonary hypertension treatment drug and application | 中国医学科学院基础医学研究所 | 2018-05-11 | — | — | CN | disclosed |
| CN-105062976-A | Stem cell screening model of pulmonary hypertension treatment drug and application | INST BASIC MED SCIENCES PLA | 2015-11-18 | — | — | CN | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| WO-2009116090-A2 | NOVEL ANTIMICROBIALS | PANACEA BIOTEC LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| CN-101479257-A | Pyrimidine and quinazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2044054-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | FDPS 1889/4885LTA4H 1706/4885MKNK2 2613/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | FDPS 1889/4885LTA4H 1706/4885MKNK2 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.